



*The Abdus Salam  
International Centre for Theoretical Physics*



310/1828

310/15

## **Workshop on Biomedical Applications of High Energy Ion Beams**

**Co-sponsored by: ICGEB and University of Surrey**

---

**12-16 February 2007**

**Venue:  
Adriatico Guest House Giambiasi Lecture Hall  
ICTP, Trieste, Italy**

---

## **Biomedical Applications of AMS: Introduction**

**Claudio TUNIZ  
ICTP, Italy**

---


# Biomolecular tracing through accelerator mass spectrometry

Claudio Tuniz  
ICTP

Biomedical Applications of High Energy Ion Beams

Trieste, 12-16 February 2007





The Abdus Salam International Centre for Theoretical Physics





# Major scientific Institutions in Trieste




# ICTP



- Founded\* in 1964, ICTP operates under a tripartite agreement between two United Nations Agencies—UNESCO and IAEA—and the Government of Italy.
- ICTP's mission is **to foster the growth of advanced studies and research in developing countries.**
- Some base funding is provided by UNESCO and IAEA, some programmatic funding by SIDA, the Kuwait Foundation and others, but the largest (~82%) of the Center's budget comes from Italy.
- ICTP's working principle is **that creating scientific knowledge is important and sharing it with others is at least as important.**

-----  
\*by Abdus Salam, 1979 Nobel Laureate in Physics.

**ICTP is an institution run by a few scientists for the benefit of many**




## ICTP Scientists, Visitors and their Functions

+ about 125 general staff

# Scientific groups

1. **High energy, cosmology and astroparticle physics**
2. **Condensed matter, statistical physics**
3. **Mathematics**
4. **Earth System Physics**
5. **Applied Physics**  
optics and lasers; medical physics; energy
6. **Laboratory activities** Mlab; scientific computing;  
information and communication technology

# ICTP visitors statistics, 1970-2003



DC: 50% visitors, 75% p-m

area	visitors	p-m	area	visitors	p-m
North America	7851	4483	Africa	9190	14596
Latin America	8013	12021	Middle East and South Asia	11760	18404
Western America	30010	17526	South East Asia and the Pacific	1420	1857
Eastern Europe	13740	14488	Far East	7000	13576

v=visitors p-m=person-months

**Quality and diversity are NOT incompatible**



# The new ICTP multidisciplinary laboratory

---



- ICTP-INFN Microprocessor Laboratory
- Plasma Focus
- Advanced X-Ray Imaging
- Accelerator mass spectrometry
- Remote access

# Plasma Focus Laboratory

---



Source of neutron and x-rays

- Training
- Biomedicine
- Materials science
- Cultural heritage

(with ENEA, Pirelli, Poland, Chile, Russian Federation)

# Outline



- 
- AMS: basic concepts
  - biomed applications of long-lived radio-nuclides
  - future prospects

# Isotopic tracers in biomedicine

---



- 1910 existence of isotopes demonstrated (F. Soddy)
- 1930's nutrition studies ( $^{15}\text{N}$ ,  $^{13}\text{C}$ ,  $^{18}\text{O}$ , ...)
- 1930's cyclotrons (radiotracers)
- 1970's ICPMS
- 1990s AMS in biomedicine

# Toxicology, Pharmacology, Nutrition

---

- Are data obtained from high-dose experiments relevant?
  - Is it possible to determine the impact of low, environmentally-relevant exposures?
- Are animal models valid?
  - Are studies with human subjects feasible?

AMS provides the sensitivity and precision needed to address these questions





# Accelerator Mass Spectrometry

---




Accelerator mass spectrometry (AMS) is an analytical technique that uses an ion accelerator to measure very small quantities of rare, long-lived isotopes (e.g.  $^{14}\text{C}$ ).

AMS was first applied to geochemical, climatological and archaeological areas, such as for radiocarbon dating, but more recently this technology has been used in biomedicine.



# Counting atoms




# Atom counters







# Table-top AMS systems



**Table 1.1** Long-Lived Radioisotopes Routinely Measured by AMS

Radioisotope	$^{10}\text{Be}$	$^{14}\text{C}$	$^{26}\text{Al}$	$^{36}\text{Cl}$	$^{41}\text{Ca}$	$^{129}\text{I}$
Half-life (a)	1.51 M	5.73 k	720 k	301 k	103 k	15.7 M
Stable isotopes	$^9\text{Be}$	$^{12,13}\text{C}$	$^{27}\text{Al}$	$^{35,37}\text{Cl}$	$^{40,42,43,44}\text{Ca}$	$^{127}\text{I}$
Stable isobars	$^{10}\text{B}$	$^{14}\text{N}^a$	$^{26}\text{Mg}^a$	$^{36}\text{Ar},^a\ ^{36}\text{S}$	$^{41}\text{K}$	$^{129}\text{Xe}^a$
Chemical form	BeO	C	$\text{Al}_2\text{O}_3$	AgCl	$\text{CaH}_2 / \text{CaF}_2$	AgI
Sample size (mg)	0.5	0.02–1	2	1	10	2
Sensitivity (atom ratio)	$2 \times 10^{-15}$	$1 \times 10^{-15}$	$2 \times 10^{-15}$	$1 \times 10^{-15}$	$5 \times 10^{-15}$	$5 \times 10^{-14}$

<sup>a</sup> Do not form negative ions.


# AMS in molecular biomedicine



- Precisely quantifies zeptomoles ( $10^{-21}$ ) to attomoles ( $10^{-18}$ ) of long lived isotopes, such as  $^{14}\text{C}$ 
  - molecular labels in metabolic studies of nutrients, toxins, hormones and therapeutics (animals, human volunteers, cells).

[DNA binding traditionally measured by tagging the chemical of interest with carbon-14 or hydrogen-3, counting the isotope label still covalently bound to DNA]

# Biological response vs dose



Immunoassay  
1 adduct/ $10^8$  nucleotides

$^{32}\text{P}$ -postlabelling  
1 adduct /  $10^{10}$  nucleotides

AMS  
< 1 adduct/  $10^{12}$  nucleotides

# Advantages



- 
- Exposure at environmental concentrations.
  - Radiologic exposures much lower than normal background
  - Long-term studies (tracing metabolites for months after a single dose of retained compound)



# Drug metabolism



- Adsorption, distribution, metabolism and excretion study using only 10 nanoCurie (37 Bq or ca. 0.9  $\mu$ Sv) of  $^{14}\text{C}$ -labelled drugs.
  - no need of regulatory approval
  - reduce waste disposal problems
  - conduct "first into man" studies (without the need for widespread use of animals)
  - high throughput and relatively low costs

# Toxicology of carcinogens



- Techniques: mass spectrometry, liquid chromatography, electrophoresis, fluorescence spectroscopy, radiotracer methods and accelerator mass spectrometry.
  - bioavailability of carcinogens;
  - carcinogens bound to DNA and protein;
- Objective: accurately estimate risk
  - understand specific molecular modifications caused by exposure to carcinogens
  - Identify specific dietary factors (e.g. heterocyclic amines that form in meat through cooking, solvents and common pollutants such as benzene, etc.)

# Carcinogen studies by $^{14}\text{C}$ -AMS




**TABLE 1: Carcinogens Studied by  $^{14}\text{C}$ -AMS**


Carcinogen	Biomolecular research
MeIQx, 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline	DNA adducts in mouse liver <sup>3</sup> DNA adducts in rat liver and distribution <sup>9</sup> Hemoglobin (Hb), albumin adducts in rat and human <sup>10</sup> Metabolism in human urine <sup>11</sup> Distribution and DNA adducts in human and rodent colon <sup>12</sup> DNA adducts in rodent and human colon <sup>13</sup>
TCDD, 2,3,7,8-tetra-Chlorodibenzo-p-dioxin	DNA adducts in mouse liver, not observed <sup>6</sup>
PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine	DNA adducts in mouse liver, lung, heart and metabolites; fate and distribution in mouse <sup>14</sup> Distribution and metabolism in female rats and their pups <sup>15</sup> DNA and protein adducts in human colon and blood <sup>16</sup> Colon DNA adducts and metabolites in urine of human and rat <sup>17</sup>
Benzene	DNA and protein adducts in mouse mallow chromosome; distribution and liver DNA adducts in mouse <sup>18</sup> DNA adducts in liver and mallow of rat and mouse <sup>19</sup>
Trichloroethylene	DNA and protein adducts in mouse liver <sup>20</sup> Initial uptake kinetics in human skin <sup>21</sup>
NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone	DNA adduct in mouse liver <sup>7</sup> Decay kinetics of adducts <sup>8</sup>

*Journal of Nuclear and Radiochemical Sciences, Vol. 2, No. 1-2, pp. R9-R12, 2001*


# MeIQX: Carcinogen from cooked meat



Turteltaub et al, LLNL




# Different responses to low and high doses of MeIQx, from cooked meat [*men are not mice!*]






# Inhibitory effects




Inhibitory effects of pretreatment with curcumin (Cur), garlic squeeze (Gar), grapeseed extract (Gra), tea polyphenols (Tea), vitamin C (VitC) and vitamin E (VitE) on nicotine (Cont)-DNA adduct formation in mice. The values at the top of each bar indicate the percent of inhibitory effects (% of elimination) of dietary constituents on nicotine-DNA adduct formation, compared with the control (as 100%). Agent injections, each day x 5 days. Nicotine 6<sup>th</sup> day, 18.2 µg/kg.

[~ 1 cigarette]

# Atrazine



# Tracking 35 micrograms of folic acid through a human for 200 days



A single dose of carbon-14-tagged folic acid was traced for 200 days. (a) The tagged folic acid appears very quickly in plasma (the liquid part of blood) and tapers off in about two days. (b) The amounts of tagged folate being eliminated in feces and urine were followed for 40 days. (c) Folate begins to be incorporated into hemoglobin at day 5. (Hemoglobin is the iron-containing, oxygen-carrying molecule in red blood cells.) The level of folate in hemoglobin peaks at about the 30th day and disappears only after 200 days.

# Isotopes for biomedical applications

---

Isotope	$t_{1/2}$	Sensitivity	Applications
$^3\text{H}$	12.3 a	$10^{-14}$	General
$^7\text{Be}$	53.3 d	$10^{-15}$	Metabolism, toxicology
$^{10}\text{Be}$	$1.51 \times 10^6$ a	$2 \times 10^{-15}$	Metabolism, toxicology
$^{14}\text{C}$	5730 a	$1 \times 10^{-15}$	General
$^{26}\text{Al}$	$7.20 \times 10^5$ a	$2 \times 10^{-15}$	Metabolism
$^{32}\text{Si}$	$\sim 140$ a	$10^{-13}$	Bone
$^{36}\text{Cl}$	$3.01 \times 10^5$ a	$1 \times 10^{-15}$	Metabolism
$^{41}\text{Ca}$	$1.03 \times 10^5$ a	$5 \times 10^{-15}$	Bone
$^{53}\text{Mn}$	$3.7 \times 10^6$ a	$10^{-10}$	Metabolism
$^{60}\text{Fe}$	$1.5 \times 10^6$ a	$10^{-12}$	Metabolism
$^{79}\text{Se}$	$\sim 1.1 \times 10^6$ a	—	Metabolism
$^{129}\text{I}$	$1.57 \times 10^7$ a	$5 \times 10^{-14}$	Metabolism

Source: From Vogel, J.S. and Turteltaub K.W., *Trends Analyt. Chem.*, 11(4), 142, 1992. With permission.

# Aluminium metabolism



- Humans evolved with aluminium oxide in the environment, but not elemental aluminium which was introduced by refining techniques during 1800s.
  - Antiperspirants and deodorants
  - Water treatment

→ anaemia, dementia, bone disease, Alzheimer (?)

# **Uptake of trace amounts of aluminium into the brain from drinking water**

---



Gavaged simulated tap water, containing 100 nanogram  $^{26}\text{Al}$  (700 kyr) into the stomach of rats.

AMS analysis of brain samples shows that trace amounts of  $^{26}\text{Al}$  from this single exposure directly entered the brain tissue, with fractions 30-300 ppb of input dose


*(Neurotoxicology, Walton, Tuniz, Fink, Jacobsen, Wilcox, 1995)*



# Toxicity of aluminium in humans




- $10^{15}$   $^{26}\text{Al}$  atoms (50 ng)  $\rightarrow$  human volunteer
- $10^6$  atoms detected by AMS (blood, urine, ...)



Priest et al, Human Experimental Toxicology, 1995

# Bone metabolism




# $^{41}\text{Ca}$ for bone loss studies



Volunteer injected  
125 ng  $^{41}\text{Ca}$



Dose commitment  
0.42 mSv in 50 yr



# Absorption of inhaled Pu from the lung

[Fiefield et al. Australian National University]




Inhalation is the main route of intake of radioactive materials for workers in nuclear industries.

How quickly, and how much is absorbed into the blood from the lungs?

NRPB (UK) study - two volunteers inhaled an aerosol with  $^{237}\text{Pu}$  (46 days) and  $^{244}\text{Pu}$  (80 Ma).

Measure Pu in blood and urine:  $^{237}\text{Pu}$  - K X-rays for 10 days  $^{244}\text{Pu}$  – by AMS for 3 years

## Pu IN BLOOD AFTER INHALATION, Subject D



# Active AMS biomed labs



US: Dedicated system at LLNL

UK: Dedicated system in YORK

Part-time centres in Sweden, France, Germany, China, Japan, Israel and Australia





# Concluding ....

---



- AMS has the sensitivity and precision to address a multitude of biomedical questions
- Merging the fields of physics, chemistry and biology (as well as others) will continue to create new insights and opportunities
- Newer, smaller spectrometers will proliferate over the next ten years



---

**Thanks!**